Taft Secures Federal Appeals Court Victory for Client Bionpharma
March 26, 2022
March 26, 2022
MINNEAPOLIS, Minnesota, March 26 -- Taft, a law firm, issued the following news:
Taft Chicago partners Andrew M. Alul and Roshan P. Shrestha, Ph.D., secured a significant Federal appeals court victory for generic drug client, Bionpharma Inc. ("Bionpharma"). Bionpharma markets a 1.0 mg/mL enalapril maleate oral solution as generic to Azurity Pharmaceuticals, Inc.'s ("Azurity," formerly Silvergate Pharmaceuticals, Inc.) Epaned(R), a prescription drug product u . . .
Taft Chicago partners Andrew M. Alul and Roshan P. Shrestha, Ph.D., secured a significant Federal appeals court victory for generic drug client, Bionpharma Inc. ("Bionpharma"). Bionpharma markets a 1.0 mg/mL enalapril maleate oral solution as generic to Azurity Pharmaceuticals, Inc.'s ("Azurity," formerly Silvergate Pharmaceuticals, Inc.) Epaned(R), a prescription drug product u . . .